SCHEMBL5160977

SCHEMBL5160977

COC(=O)CC(=O)c1ncccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.47
CTNNB1 P35222 1/20 0.44
WNT3A P56704 1/20 0.44
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
KMT2A Q03164 2/20 0.38
LMNA P02545 3/20 0.37
HTT P42858 1/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.37
PKM P14618 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
RAB9A P51151 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1505564 0.82 MGAM (0.50) P2RX7CTNNB1WNT3AALDH1A1SMN1; SMN2
SCHEMBL5162472 0.81 TSHR (0.43) P2RX7CTNNB1WNT3AALDH1A1SMN1; SMN2
SCHEMBL5159978 0.81 P2RX7 (0.41) P2RX7CTNNB1WNT3AALDH1A1L3MBTL1
SCHEMBL15096486 0.78 LMNA (0.53) P2RX7CTNNB1WNT3AALDH1A1SMN1; SMN2
SCHEMBL852344 0.77 SMN1; SMN2 (0.57) CTNNB1WNT3AALDH1A1SMN1; SMN2LMNA
SCHEMBL3406277 0.77 MTNR1A (0.45) ALDH1A1SMN1; SMN2KMT2ATSHRMEN1
SCHEMBL5158464 0.75 P2RX7 (0.47) P2RX7CTNNB1WNT3AALDH1A1SMN1; SMN2
SCHEMBL18622307 0.75 P2RX7 (0.47) P2RX7CTNNB1WNT3AALDH1A1SMN1; SMN2
SCHEMBL10479222 0.75 P2RX7 (0.52) P2RX7ALDH1A1SMN1; SMN2GAAKMT2A
SCHEMBL5159948 0.74 P2RX7 (0.61) P2RX7CTNNB1WNT3AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO P2RX7 2943/4885CTNNB1 3075/4885WNT3A 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.